Groundbreaking UK Bowel Cancer Trial Reports Zero Relapses After Three Years
A landmark UK clinical trial for a specific type of bowel cancer has delivered extraordinary results, with every single one of the 32 patients involved remaining cancer-free nearly three years after treatment — offering tremendous hope for a new standard of care that could transform outcomes for thousands of patients.
The trial, which used the immunotherapy drug pembrolizumab to treat patients with MMR deficient/MSI-high bowel cancer, was announced on 24 April 2026 and has been hailed as a major breakthrough in the field of oncology.
Background
Bowel cancer is the fourth most common cancer in the UK, with around 42,000 new cases diagnosed each year. MMR deficient/MSI-high bowel cancer is a specific subtype, characterised by a defect in the DNA mismatch repair system, which makes it particularly responsive to immunotherapy. Pembrolizumab, marketed as Keytruda, is an immunotherapy drug that works by helping the immune system to recognise and attack cancer cells.
Key Developments
The trial, led by researchers at University College London, enrolled 32 patients with MMR deficient/MSI-high bowel cancer who were treated with pembrolizumab instead of the standard treatment of surgery and chemotherapy. After nearly three years of follow-up, not a single patient had experienced a relapse. According to UCL News, the results represent a remarkable step forward and suggest that immunotherapy could potentially replace surgery and chemotherapy for this patient group, sparing them from the significant side effects of conventional treatment. The findings were published in a leading medical journal on 24 April.
Why It Matters
The results offer hope not just for the 32 patients in the trial, but for the thousands of people diagnosed with MMR deficient/MSI-high bowel cancer each year in the UK and around the world. If the findings are confirmed in larger trials, pembrolizumab could become the standard of care for this patient group, potentially replacing the need for major surgery and toxic chemotherapy. The trial also demonstrates the transformative potential of immunotherapy in treating cancer more broadly.
What's Next
The researchers are now planning a larger trial to confirm the findings and explore whether the approach can be extended to other types of bowel cancer. They are also investigating whether the treatment can be used in patients with more advanced disease. If the results hold up in larger studies, the next step would be to seek regulatory approval for pembrolizumab as a first-line treatment for MMR deficient/MSI-high bowel cancer, which could happen within the next few years.
